Maintenance

Maintenance Rituxan for CLL

Rituximab has been shown to prolong survival when used therapeutically with chemotherapy in Chronic Lymphocytic Leukemia(CLL). Rituximab, the mAb targeting CD20, was approved by the US FDA for patients with relapsed low-grade non-Hodgkin lymphoma. It is counterintuitive why Rituxan works in CLL. Relatively low levels of CD20 are expressed on CLL B cells, compared to normal B or neoplastic B cells of other lymphomas. In addition, soluble CD20 has

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39